导电系统节奏与慢性心力衰竭中的双管节奏:PhysioSync-HF试验经济分析协议
Sérgio R R Decker1,2,3,4, Ana Paula Beck da S Etges5,6,7, André Zimerman3,4,8,9
1Serviço de Clínica Médica do Hospital Moinhos de Vento, Porto Alegre, RS - Brasil.
Arquivos brasileiros de cardiologia
|March 4, 2026
概括
导电系统节奏 (CSP) 为心力衰竭患者的心脏再同步疗法 (CRT) 提供了一种成本效益高的替代双心室节奏 (BVP) 疗法. 本试验评估了CSP的经济效益,可能改善对CRT的访问.
科学领域:
- 心脏病学 心脏病学
- 卫生经济学 卫生经济学
- 临床试验 临床试验
背景情况:
- 导电系统节奏 (CSP) 是用于心脏再同步治疗 (CRT) 的双心脏节奏 (BVP) 的新兴替代方案.
- 与BVP相比,CSP具有潜在的临床优势和成本降低.
- 物理同步-HF试验是一项多中心,随机的研究,评估CSP与BVP在心力衰竭中减少射出分数 (HFrEF).
研究的目的:
- 概述 PhysioSync-HF 试验中整合的经济评估的理由和设计.
- 为了比较CSP与BVP对HFrEF患者CRT的经济影响.
- 评估成本节约的潜力和改善对CRT的访问.
主要方法:
- 该PhysioSync-HF试验包括179名患者,随访期为1年.
- 基于时间驱动的基于活动的成本计算和基于资源的会计方法被用于收集程序和后续成本.
- 统计分析解决了缺少的数据和扭曲的成本分布.
主要成果:
- 主要经济终点是CSP和BVP组在1年内每名患者的总直接医疗费用差异.
- 二次结果包括详细的成本组件细分和对巴西医疗保健系统的预算影响分析.
- 经济评估旨在确定与CSP相关的成本节约机会.
结论:
- 在PhysioSync-HF试验中的这一经济评估提供了关于CSP与BVP的成本效益的关键数据.
- 这些发现旨在支持巴西HFrEF患者扩大对CRT的公平获得.
- 该研究提供了与全球医疗保健环境相关的关于CRT成本优化的见解.
相关概念视频
Heart Failure II: Pathophysiology
1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Conduction System of the Heart
14.2K
Autorhythmicity is a term that refers to the heart's inherent ability to generate electrical signals and instigate muscle contractions. This self-regulating conduction system within the heart consists of two key components: the pacemaker cells and specialized conducting cells.
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
14.2K
Conduction System of the Heart
4.7K
The cardiac conduction system produces and transmits electrical impulses that prompt myocardial contraction, ensuring efficient heart function. This intricate system ensures that the heart beats in a coordinated and efficient manner, beginning with the atria and then the ventricles. The conduction system optimizes cardiac output by maintaining this precise sequence, which is crucial for adequate blood circulation.
This system relies on the unique properties of nodal and Purkinje cells:...
This system relies on the unique properties of nodal and Purkinje cells:...
4.7K
Pathophysiology of Heart Failure
4.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K
Heart Failure Drugs: Inotropic Agents
1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Heart Failure Drugs: β-Blockers
1.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K


